標(biāo)題: Titlebook: Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management; Aamir Ahmad,Shirish M. Gadgeel Book 2016 The Editor(s) (if [打印本頁] 作者: 欺騙某人 時間: 2025-3-21 17:58
書目名稱Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management影響因子(影響力)
書目名稱Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management影響因子(影響力)學(xué)科排名
書目名稱Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management網(wǎng)絡(luò)公開度
書目名稱Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management被引頻次
書目名稱Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management被引頻次學(xué)科排名
書目名稱Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management年度引用
書目名稱Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management年度引用學(xué)科排名
書目名稱Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management讀者反饋
書目名稱Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management讀者反饋學(xué)科排名
作者: 內(nèi)向者 時間: 2025-3-21 22:29 作者: FIR 時間: 2025-3-22 01:40
Philip T. Cagle M.D.,Kirtee Raparia M.D.,Bryce P. Portier M.D., Ph.D.niumbauteilen. Im diesem Kapitel wird zun?chst auf die dabei auftretenden Herausforderung der signifikant erh?hten Schwei?nahtporosit?t im Vergleich zu konventionell hergestelltem Material (z.B. Guss) dargestellt. Auf Basis dieses Porenph?nomens wird als Forschungsziel definiert, ein tiefes Verst?nd作者: 雪崩 時間: 2025-3-22 08:19
Vivek Mittalniumbauteilen. Im diesem Kapitel wird zun?chst auf die dabei auftretenden Herausforderung der signifikant erh?hten Schwei?nahtporosit?t im Vergleich zu konventionell hergestelltem Material (z.B. Guss) dargestellt. Auf Basis dieses Porenph?nomens wird als Forschungsziel definiert, ein tiefes Verst?nd作者: 喊叫 時間: 2025-3-22 10:02
Raagini Suresh,Shadan Ali,Aamir Ahmad,Philip A. Philip,Fazlul H. Sarkar Hindernis für die industrielle Nutzung des Laserstrahlschwei?ens von Aluminiumlegierungen im Leichtbau. Vor diesem Hintergrund wird in der vorliegenden Arbeit eine umfassende Charakterisierung der Laserschwei?eignung dieser Materialgruppe erstellt und die oben erw?hnte Lücke dadurch geschlossen.Zue作者: Seminar 時間: 2025-3-22 13:06
Vivek Mittal,Tina El Rayes,Navneet Narula,Timothy E. McGraw,Nasser K Altorki,Mary Helen Barcellos-Ho Hindernis für die industrielle Nutzung des Laserstrahlschwei?ens von Aluminiumlegierungen im Leichtbau. Vor diesem Hintergrund wird in der vorliegenden Arbeit eine umfassende Charakterisierung der Laserschwei?eignung dieser Materialgruppe erstellt und die oben erw?hnte Lücke dadurch geschlossen.Zue作者: NIL 時間: 2025-3-22 18:34
Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development,in several decades. Recently, however, molecular and genomic profiling of the lung tumors has revealed recurring somatic mutations. As a result the therapeutic landscape of lung cancer is undergoing a paradigm shift from a purely histology-based understanding of the disease to subtype distinctions b作者: Condescending 時間: 2025-3-23 00:45
Emerging Biomarkers in Personalized Therapy of Lung Cancer,nd anaplastic lymphoma kinase (.) translocations) occur in only about 20 % of lung adenocarcinomas and acquired resistance develops to first generation drugs. Several other oncogenic drivers for lung adenocarcinoma have emerged as potentially druggable targets with new predictive biomarkers. Oncolog作者: 微粒 時間: 2025-3-23 01:21
Epithelial Mesenchymal Transition in Aggressive Lung Cancers,ent of metastasis is an unmet clinical need. Epithelial to mesenchymal transition (EMT) is an evolutionary conserved developmental program, which is induced during cancer progression and contributes to metastatic colonization. EMT endows metastatic properties upon cancer cells by enhancing mobility,作者: RAGE 時間: 2025-3-23 05:55 作者: 剛開始 時間: 2025-3-23 09:59 作者: Colonnade 時間: 2025-3-23 14:14 作者: Ancestor 時間: 2025-3-23 18:38 作者: Femish 時間: 2025-3-23 22:20 作者: 比賽用背帶 時間: 2025-3-24 03:26
Personalized Therapy of Small Cell Lung Cancer,acteristics. Despite robust responses to initial chemotherapy and radiation, the prognosis of patients with SCLC remains poor with an overall 5-year survival rate of less than 10 %. Despite the fact that numerous molecularly targeted approaches have thus far failed to demonstrate clinical utility in作者: 才能 時間: 2025-3-24 06:48 作者: 車床 時間: 2025-3-24 12:20 作者: Breach 時間: 2025-3-24 18:12
https://doi.org/10.1007/978-3-319-24932-2Lung cancer; Genomics; Therapeutic Implications; Stem Cells; Small Cell Lung Cancer; Radiation Therapy作者: Comprise 時間: 2025-3-24 20:12
978-3-319-79702-1The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: Facet-Joints 時間: 2025-3-25 01:50
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management978-3-319-24932-2Series ISSN 0065-2598 Series E-ISSN 2214-8019 作者: metropolitan 時間: 2025-3-25 04:08
Aamir Ahmad,Shirish M. GadgeelProvides a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans.Addresses statistics and epidemiology of lung c作者: 流浪者 時間: 2025-3-25 08:33 作者: Suggestions 時間: 2025-3-25 12:24 作者: 懸崖 時間: 2025-3-25 18:33 作者: 能量守恒 時間: 2025-3-25 20:08 作者: BALK 時間: 2025-3-26 04:03 作者: 天氣 時間: 2025-3-26 06:53 作者: expdient 時間: 2025-3-26 10:30
of ～10., were extremely rich but certainly contained many lines which were instrumentally broadened. In the 1930’s, Otto Deutschbein working in Marburg [3] carried out extensive measurements of the spectra of chromium ions in natural crystals of many materials including ruby, spinel, alexandrite and作者: botany 時間: 2025-3-26 15:41
Philip T. Cagle M.D.,Kirtee Raparia M.D.,Bryce P. Portier M.D., Ph.D.s den drei Einflussgr??en Werkstoff (Schwei?eignung), Fertigung (Schwei?m?glichkeit) und Konstruktion (Schwei?sicherheit) ergibt. Entsprechend sind die Analysen dieser Arbeit aufgebaut. Weiterhin wird im Anschnitt ?Vorgehensweise“ das genutzte L-PBF- und Laserschwei?equipment dargestellt sowie die s作者: 遺忘 時間: 2025-3-26 17:33 作者: stroke 時間: 2025-3-26 22:59
Raagini Suresh,Shadan Ali,Aamir Ahmad,Philip A. Philip,Fazlul H. Sarkard unter Einbeziehung theoretischer Proze?modelle wird gezeigt, da? das Tandem-Laserstrahlschwei?en ein effektives Verfahren zur Proze?stabilisierung beim Tiefschwei?en und damit zur Vermeidung von Proze?poren und Schmelzauswürfen ist.In einem weiteren Teil der Arbeit werden die metallurgischen Eigen作者: Forehead-Lift 時間: 2025-3-27 02:59
Vivek Mittal,Tina El Rayes,Navneet Narula,Timothy E. McGraw,Nasser K Altorki,Mary Helen Barcellos-Hod unter Einbeziehung theoretischer Proze?modelle wird gezeigt, da? das Tandem-Laserstrahlschwei?en ein effektives Verfahren zur Proze?stabilisierung beim Tiefschwei?en und damit zur Vermeidung von Proze?poren und Schmelzauswürfen ist.In einem weiteren Teil der Arbeit werden die metallurgischen Eigen作者: heterogeneous 時間: 2025-3-27 08:36
Kristina M. Kruglyak Ph.D.,Erick Lin M.D., Ph.D.,Frank S. Ong M.D.作者: 我沒有命令 時間: 2025-3-27 10:15 作者: 母豬 時間: 2025-3-27 16:51 作者: 含鐵 時間: 2025-3-27 20:47 作者: Annotate 時間: 2025-3-28 00:08
Emerging Biomarkers in Personalized Therapy of Lung Cancer,ing by immunohistochemistry may be useful for some biomarkers (ROS1, BRAF). Targeted next generation sequencing techniques may be useful as well. These five biomarkers are under consideration for inclusion in revised lung cancer biomarker guidelines by the College of American Pathologists, Internati作者: 聯(lián)合 時間: 2025-3-28 06:09
Epithelial Mesenchymal Transition in Aggressive Lung Cancers,chanisms underlying EMT/MET in tumor invasion, dissemination and metastasis. In this chapter, we will focus on the contribution of the EMT signaling pathways in lung cancer progression, cancer stem cells and acquired resistance to EGFR tyrosine kinase inhibitors and chemotherapy. We will also discus作者: 大廳 時間: 2025-3-28 09:47 作者: Calibrate 時間: 2025-3-28 10:47 作者: Inexorable 時間: 2025-3-28 15:16
Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer, medicine. Towards this end, NGS has already been used to identify new biomarker candidates for the early diagnosis of lung cancer and is increasingly used to guide personalized treatment decisions. In this review we will provide a high-level overview of NGS technology and summarize its application 作者: Gum-Disease 時間: 2025-3-28 22:09 作者: RODE 時間: 2025-3-29 02:58
Personalized Therapy of Small Cell Lung Cancer,evaluated in SCLC and many studies of these strategies are on-going. Perhaps the most promising approaches involve agents targeting cancer stem cell pathways and immunomodulatory drugs that interfere with the PD1 and CTLA-4 pathways. SCLC offers many barriers to the development of successful therapy作者: surrogate 時間: 2025-3-29 04:34
Personalized Radiation Therapy (PRT) for Lung Cancer,s, metabolomics from tumor and blood samples, and radiomics from PET, CT, SPECT images. Finally, RT fractionation schedule may also be personalized to each individual patient to maximize therapeutic gain. Future PRT should be based on comprehensive considerations of knowledge acquired from all these作者: NADIR 時間: 2025-3-29 07:15 作者: ostrish 時間: 2025-3-29 14:24 作者: engrossed 時間: 2025-3-29 19:14
Priyanga Wijesinghe Ph.D.,Aliccia Bollig-Fischer Ph.D.ell Telephone Laboratories, and Stan- ford University. But, as is illustrated by the papers of this volume, its effects and his personal infiuence have diffused978-3-662-13608-9978-3-540-47872-0Series ISSN 0342-4111 Series E-ISSN 1556-1534
